NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

Core Insights - Quoin Pharmaceuticals Ltd. has launched the NETHERTON NOW awareness campaign to increase visibility for Netherton Syndrome, a rare genetic disease with no approved treatment or cure [4][8][12] - The campaign has achieved significant engagement, with nearly 2 million video views and over 24 million impressions globally, highlighting the need for awareness and action in addressing this neglected disease [9][10] Company Initiatives - The NETHERTON NOW campaign was initiated at the beginning of Rare Disease Month 2025 to amplify the voices of patients, caregivers, and clinicians affected by Netherton Syndrome [8][9] - The campaign features patient stories and educational content, aiming to foster understanding and support within the medical and advocacy communities [10][11] Disease Overview - Netherton Syndrome is characterized by excessive skin shedding, chronic inflammation, and recurrent infections, leading to severe complications and a high mortality rate in newborns [8] - Approximately 10–20% of newborns with Netherton Syndrome do not survive, and those who do often face lifelong health challenges [8] Future Directions - Quoin Pharmaceuticals is committed to advancing clinical research and regulatory pathways for potential treatments, including their lead investigational candidate QRX003, which is currently in late-stage pivotal clinical trials [12][14] - The company emphasizes the importance of not only raising awareness but also ensuring access to safe and effective treatments for patients and families affected by Netherton Syndrome [11][12]